Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials

被引：17

作者：

Mkhize, Nonhlanhla N. ^{[1
,2
]}

Yssel, Anna ^{[3
]}

Kaldine, Haajira ^{[1
,2
]}

van Dorsten, Rebecca T. ^{[1
,2
,4
]}

Davis, Amanda S. ^{[5
]}

Beaume, Nicolas ^{[3
]}

Matten, David ^{[3
]}

Lambson, Bronwen ^{[1
,2
]}

Modise, Tandile ^{[1
,2
]}

Kgagudi, Prudence ^{[1
,2
]}

York, Talita ^{[3
]}

Westfall, Dylan H. ^{[6
]}

Giorgi, Elena E. ^{[5
]}

Korber, Bette ^{[7
]}

Anthony, Colin ^{[3
]}

Mapengo, Rutendo E. ^{[1
,2
]}

Bekker, Valerie ^{[1
]}

Domin, Elizabeth ^{[8
]}

Eaton, Amanda ^{[8
]}

Deng, Wenjie ^{[6
]}

DeCamp, Allan ^{[5
]}

Huang, Yunda ^{[5
]}

Gilbert, Peter B. ^{[5
]}

Gwashu-Nyangiwe, Asanda ^{[3
]}

Thebus, Ruwayhida ^{[3
]}

Ndabambi, Nonkululeko ^{[3
]}

Mielke, Dieter ^{[3
,8
]}

Mgodi, Nyaradzo ^{[9
]}

Karuna, Shelly ^{[5
]}

Edupuganti, Srilatha ^{[10
]}

Seaman, Michael S. ^{[11
]}

Corey, Lawrence ^{[5
,12
]}

Cohen, Myron S. ^{[13
]}

Hural, John ^{[5
]}

McElrath, M. Juliana ^{[5
]}

Mullins, James I. ^{[6
]}

Montefiori, David ^{[8
]}

Moore, Penny L. ^{[1
,2
,14
]}

Williamson, Carolyn ^{[3
,14
,15
]}

Morris, Lynn ^{[1
,2
,14
]}

机构：

[1] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Johannesburg, South Africa

[2] Univ Witwatersrand, Fac Hlth Sci, SA MRC Antibody Immun Res Unit, Johannesburg, South Africa

[3] Univ Cape Town, Inst Infect Dis & Mol Med, Fac Hlth Sci, Div Med Virol, Cape Town, South Africa

[4] Univ Witwatersrand, Sch Pathol, South African Med Res Council, Fac Hlth Sci,Antiviral Gene Therapy Res Unit, Johannesburg, South Africa

[5] Fred Hutchinson Canc Ctr, Vaccine & Infect Dis Div, Seattle, WA USA

[6] Univ Washington, Dept Microbiol, Seattle, WA USA

[7] Los Alamos Natl Lab, Los Alamos, NM USA

[8] Duke Univ, Dept Surg, Durham, NC USA

[9] Univ Zimbabwe, Coll Hlth Sci, Clin Trials Res Ctr, Harare, Zimbabwe

[10] Emory Univ, Dept Med, Div Infect Dis, Decatur, GA USA

[11] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA USA

[12] Univ Washington, Dept Lab Med, Seattle, WA USA

[13] Univ North Carolina Chapel Hill, Dept Med, Chapel Hill, NC USA

[14] Univ KwaZulu Natal, Ctr AIDS Programme Res South Africa CAPRISA, Durban, South Africa

[15] Natl Hlth Lab Serv, Cape Town, South Africa

来源：

PLOS PATHOGENS | 2023年 / 19卷 / 06期

基金：

新加坡国家研究基金会; 美国国家卫生研究院;

关键词：

HUMAN MONOCLONAL-ANTIBODIES; HUMORAL IMMUNITY; POTENT NEUTRALIZATION; IMPROVES PROTECTION; ENVELOPE; GP120; BREADTH; BROAD; ADAPTATION; EVOLUTION;

D O I：

10.1371/journal.ppat.1011469

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The VRC01 Antibody Mediated Prevention (AMP) efficacy trials conducted between 2016 and 2020 showed for the first time that passively administered broadly neutralizing antibodies (bnAbs) could prevent HIV-1 acquisition against bnAb-sensitive viruses. HIV-1 viruses isolated from AMP participants who acquired infection during the study in the sub-Saharan African (HVTN 703/HPTN 081) and the Americas/European (HVTN 704/HPTN 085) trials represent a panel of currently circulating strains of HIV-1 and offer a unique opportunity to investigate the sensitivity of the virus to broadly neutralizing antibodies (bnAbs) being considered for clinical development. Pseudoviruses were constructed using envelope sequences from 218 individuals. The majority of viruses identified were clade B and C; with clades A, D, F and G and recombinants AC and BF detected at lower frequencies. We tested eight bnAbs in clinical development (VRC01, VRC07-523LS, 3BNC117, CAP256.25, PGDM1400, PGT121, 10-1074 and 10E8v4) for neutralization against all AMP placebo viruses (n = 76). Compared to older clade C viruses (1998-2010), the HVTN703/HPTN081 clade C viruses showed increased resistance to VRC07-523LS and CAP256.25. At a concentration of 1 & mu;g/ml (IC80), predictive modeling identified the triple combination of V3/V2-glycan/CD4bs-targeting bnAbs (10-1074/PGDM1400/VRC07-523LS) as the best against clade C viruses and a combination of MPER/V3/CD4bs-targeting bnAbs (10E8v4/10-1074/VRC07-523LS) as the best against clade B viruses, due to low coverage of V2-glycan directed bnAbs against clade B viruses. Overall, the AMP placebo viruses represent a valuable resource for defining the sensitivity of contemporaneous circulating viral strains to bnAbs and highlight the need to update reference panels regularly. Our data also suggests that combining bnAbs in passive immunization trials would improve coverage of global viruses. Author summaryHIV-1 viruses from the Antibody Mediated Prevention (AMP) trials, obtained in 2016-2020, represent our most recent panel of transmitted viruses in the population. Reference virus strains that are currently used to evaluate broadly neutralizing antibodies (bnAb) for passive immune trials and assess the quality of vaccine induced antibody responses, were collected between 1998 and 2010. As HIV-1 continues to evolve, virus panels may need to be updated from time to time. Sequences were obtained from participants infected with HIV-1 from both the African (HVTN 703/HPTN081) and the Americas/European (HVTN 704/HPTN085) AMP trials. These viruses were then tested in a neutralization assay with 8 bnAbs under clinical development. Comparing the neutralization coverage with older viruses, we found that recent viruses have become more resistant to VRC07-523LS and CAP256.25 antibodies. Predictive modelling identified triple bnAb combinations that would be effective at neutralizing HIV-1 strains from different geographical regions. Reference panels that include recently transmitted HIV-1 strains provide important information that can be used to design bnAb combinations to consider for prevention studies.

引用

页数：17

共 54 条

[1] Adaptation of HIV-1 Envelope Glycoprotein gp120 to Humoral Immunity over the Course of the Epidemic
Bouvin-Pley, Melanie
Morgand, Marion
Moreau, Alain
Meyer, Laurence
Goujard, Cecile
Mouquet, Hugo
Nussenzweig, Michel C.
Pace, Craig S.
Ho, David D.
Bjorkman, Pamela J.
Baty, Daniel
Chames, Patrick
Pancera, Marie
Kwong, Peter D.
Poignard, Pascal
Barin, Francis
Braibant, Martine
[J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 : A224 - A224
[2] HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design
Bricault, Christine A.
Yusim, Karina
Seaman, Michael S.
Yoon, Hyejin
Theiler, James
Giorgi, Elena E.
Wagh, Kshitij
Theiler, Maxwell
Hraber, Peter
Macke, Jennifer P.
Kreider, Edward F.
Learn, Gerald H.
Hahn, Beatrice H.
Scheid, Johannes F.
Kovacs, James M.
Shields, Jennifer L.
Lavine, Christy L.
Ghantous, Fadi
Rist, Michael
Bayne, Madeleine G.
Neubauer, George H.
McMahan, Katherine
Peng, Hanqin
Cheneau, Coraline
Jones, Jennifer J.
Zeng, Jie
Ochsenbauer, Christina
Nkolola, Joseph P.
Stephenson, Kathryn E.
Chen, Bing
Gnanakaran, S.
Bonsignori, Mattia
Williams, LaTonya D.
Haynes, Barton F.
Doria-Rose, Nicole
Mascola, John R.
Montefiori, David C.
Barouch, Dan H.
Korber, Bette
[J]. CELL HOST & MICROBE, 2019, 25 (01) : 59 - +
[3] Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection
Bunnik, Evelien M.
Pisas, Linaida
van Nuenen, Ad C.
Schuitemaker, Hanneke
[J]. JOURNAL OF VIROLOGY, 2008, 82 (16) : 7932 - 7941
[4] Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level
Bunnik, Evelien M.
Euler, Zelda
Welkers, Matthijs R. A.
Boeser-Nunnink, Brigitte D. M.
Grijsen, Marlous L.
Prins, Jan M.
Schuitemaker, Hanneke
[J]. NATURE MEDICINE, 2010, 16 (09) : 995 - 997
[5] Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
Caskey, Marina
Klein, Florian
Lorenzi, Julio C. C.
Seaman, Michael S.
West, Anthony P., Jr.
Buckley, Noreen
Kremer, Gisela
Nogueira, Lilian
Braunschweig, Malte
Scheid, Johannes F.
Horwitz, Joshua A.
Shimeliovich, Irina
Ben-Avraham, Sivan
Witmer-Pack, Maggi
Platten, Martin
Lehmann, Clara
Burke, Leah A.
Hawthorne, Thomas
Gorelick, Robert J.
Walker, Bruce D.
Keler, Tibor
Gulick, Roy M.
Faetkenheuer, Gerd
Schlesinger, Sarah J.
Nussenzweig, Michel C.
[J]. NATURE, 2015, 522 (7557) : 487 - +
[6] The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen
Ching, Lance K.
Vlachogiannis, Giorgos
Bosch, Katherine A.
Stamatatos, Leonidas
[J]. JOURNAL OF VIROLOGY, 2008, 82 (02) : 949 - 956
[7] Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
Corey, L.
Gilbert, P. B.
Juraska, M.
Montefiori, D. C.
Morris, L.
Karuna, S. T.
Edupuganti, S.
Mgodi, N. M.
deCamp, A. C.
Rudnicki, E.
Huang, Y.
Gonzales, P.
Cabello, R.
Orrell, C.
Lama, J. R.
Laher, F.
Lazarus, E. M.
Sanchez, J.
Frank, I.
Hinojosa, J.
Sobieszczyk, M. E.
Marshall, K. E.
Mukwekwerere, P. G.
Makhema, J.
Baden, L. R.
Mullins, J. I.
Williamson, C.
Hural, J.
McElrath, M. J.
Bentley, C.
Takuva, S.
Lorenzo, M. M. Gomez
Burns, D. N.
Espy, N.
Randhawa, A. K.
Kochar, N.
Piwowar-Manning, E.
Donnell, D. J.
Sista, N.
Andrew, P.
Kublin, J. G.
Gray, G.
Ledgerwood, J. E.
Mascola, J. R.
Cohen, M. S.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (11) : 1003 - 1014
[8] HIV-1 Envelope Subregion Length Variation during Disease Progression
Curlin, Marcel E.
Zioni, Rafael
Hawes, Stephen E.
Liu, Yi
Deng, Wenjie
Gottlieb, Geoffrey S.
Zhu, Tuofu
Mullins, James I.
[J]. PLOS PATHOGENS, 2010, 6 (12)
[9] Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies
deCamp, Allan
Hraber, Peter
Bailer, Robert T.
Seaman, Michael S.
Ochsenbauer, Christina
Kappes, John
Gottardo, Raphael
Edlefsen, Paul
Self, Steve
Tang, Haili
Greene, Kelli
Gao, Hongmei
Daniell, Xiaoju
Sarzotti-Kelsoe, Marcella
Gorny, Miroslaw K.
Zolla-Pazner, Susan
LaBranche, Celia C.
Mascola, John R.
Korber, Bette T.
Montefiori, David C.
[J]. JOURNAL OF VIROLOGY, 2014, 88 (05) : 2489 - 2507
[10] New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency
Doria-Rose, Nicole A.
Bhiman, Jinal N.
Roark, Ryan S.
Schramm, Chaim A.
Gorman, Jason
Chuang, Gwo-Yu
Pancera, Marie
Cale, Evan M.
Ernandes, Michael J.
Louder, Mark K.
Asokan, Mangaiarkarasi
Bailer, Robert T.
Druz, Aliaksandr
Fraschilla, Isabella R.
Garrett, Nigel J.
Jarosinski, Marissa
Lynch, Rebecca M.
McKee, Krisha
O'Dell, Sijy
Pegu, Amarendra
Schmidt, Stephen D.
Staupe, Ryan P.
Sutton, Matthew S.
Wang, Keyun
Wibmer, Constantinos Kurt
Haynes, Barton F.
Abdool-Karim, Salim
Shapiro, Lawrence
Kwong, Peter D.
Moore, Penny L.
Morris, Lynn
Mascola, John R.
[J]. JOURNAL OF VIROLOGY, 2016, 90 (01) : 76 - 91

← 1 2 3 4 5 6 →